Two stocks in Healthcare
Eurofins Scientific vs Novartis: profit, growth, debt and price compared
Novartis is stronger on 4 of 7 figures: profit margin, sales growth, price for its expected profit and dividend. Eurofins Scientific is stronger on 2: debt and price trend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Eurofins ScientificERF.PA | NovartisNOVN.SW | |
|---|---|---|
| Net margin | 7.2% | Stronger: 17.5% |
| Revenue growth, past year | +2.50% | Stronger: +4.70% |
| Debt to equity | Stronger: 96.1% | 128.6% |
| Forward P/E | 17.9× | Stronger: 15.9× |
| Dividend yield | 0.82% | Stronger: 2.78% |
| Analysts | Hold · 14 | Hold · 22 |
| From its 200-day average | Stronger: +18.5% | +9.2% |
Share price over the past year
- Eurofins Scientific+45.4%
- Novartis+27.7%
24 Nov 202518 Nov 2026
Eurofins Scientific or Novartis: which is stronger?
- NOVN.SW
Which is more profitable?
Novartis keeps more of each sale as profit: 17.5% against 7.2%.
- NOVN.SW
Which is growing its sales faster?
Novartis is growing its sales faster: +4.70% over the past year, against +2.50%.
- ERF.PA
Which has borrowed less?
Eurofins Scientific has borrowed less: its debt is 96.1% of what its shareholders own, against 128.6% for Novartis.
- NOVN.SW
Which costs less for the profit it is expected to make?
Novartis costs less for the profit it is expected to make: 15.9× its forward earnings, against 17.9×.
- NOVN.SW
Which pays more in dividends?
Novartis pays more back in dividends for what a share costs: 2.78% a year, against 0.82%.
Which do analysts rate higher?
Analysts rate both the same: Hold.
- ERF.PA
Which is in the stronger price trend?
Eurofins Scientific's price is in the stronger trend: 18.5% above its 200-day average, against 9.2% above.
What each company does
ERF.PAEurofins Scientific
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide.
Reports results on 28 January 2027
NOVN.SWNovartis
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Reports results on 3 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.